	Fujifilm plans to invest approximately JPY 10 billion (approximately US$90 million) to expand its biopharmaceutical contract development and manufacturing organization (CDMO) business, FUJIFILM Diosynth Biotechnologies (FDB), the company announced on Jan. 7, 2019. 

	This investment will include the expansion of existing production facilities at its North Carolina location. Further investments are planned at the company’s other locations.

	Investments will include the addition of 2000-L single-use cell-culture manufacturing trains, cell-culture purification suites, and new microbial recovery suites to its existing facilities in North Carolina. These additions will increase cell-culture manufacturing capacity by approximately 25% and microbial capacity by approximately 50% at its North Carolina location. The company expects that the increased production capacity will be ready for cGMP manufacture by early 2020. Fujifilm has committed to grow its CDMO business to meet a JPY 100 billion sales target by March 2024. 

Contract Manufacturing, Biopharmaceutical Production

Manufacturing

Manufacturing, Biologic Drugs

Outsourcing

PharmTech News

Supplier News

Fujifilm increases capacity of its Bio-CDMO business with an expansion of production in North Carolina.